Vaccine Policy, Regulatory Capture, and Health Freedom

The legal and institutional systems surrounding vaccine policy determine who bears financial risk when products cause harm, what safety evidence reaches policymakers, and whether scientists can raise concerns without losing their careers. In the United States, a 1986 law removed the right to sue vaccine manufacturers in civil courts. Similar liability protections have since been extended in other countries under emergency frameworks. Understanding how these systems were built, and how they operate, matters for anyone trying to make an informed decision about vaccination or engage meaningfully with the debate about vaccine mandates.

• In the United States, a 1986 law called the National Childhood Vaccine Injury Act removed the ability to sue vaccine manufacturers in ordinary civil courts, shifting liability onto a government-administered compensation fund
• The same law contains a fraud exception: if a manufacturer can be shown to have known their product could cause harm and concealed that knowledge, the liability shield does not apply
• Regulatory agencies that approve vaccines in many countries receive substantial funding from the companies whose products they assess, which creates a structural conflict of interest that can influence the evidence available to policymakers
• Scientists who have raised concerns about specific vaccines have in documented cases faced loss of funding, career damage, and legal action rather than open scientific investigation of their findings
• Antibody-dependent enhancement (where a vaccine primes the immune system in a way that makes a later infection worse rather than better) was publicly acknowledged as a risk for coronavirus vaccines by prominent scientists before mass deployment began
• The right to refuse a medical treatment without facing penalties is protected in law in many countries under the principle of informed consent, and this applies to vaccines as it does to any other medical procedure

How liability removal changed the vaccine industry

In the United States before 1986, vaccine manufacturers faced the same civil liability as any product company. A family whose child was harmed by a vaccine could sue the manufacturer in court, and settlements came from company funds. This created a direct financial incentive to invest in product safety before widespread use.

The National Childhood Vaccine Injury Act, passed in the United States in 1986, fundamentally changed this. It moved vaccine injury claims into a specialist federal compensation programme funded by an excise tax on vaccines paid at the point of purchase. Manufacturers were shielded from direct civil liability. Injured parties lost access to the ordinary civil court system and were limited to a government-administered process with narrow eligibility criteria and a historically low approval rate.

Critics of this arrangement argue that removing civil liability removed the most powerful market mechanism for safety accountability. A company that cannot be sued for harm caused by its products has less incentive to invest in long-term safety monitoring or to develop safer formulations when alternatives exist. Legal advocates working in this field argue the same structural weakness applies in other countries where emergency use authorisation frameworks include broad liability protections for manufacturers.

The 1986 Act contains one significant legal crack. It does not protect manufacturers who can be shown to have committed fraud. Fraud in this context means knowing that a product could be made safer, or that it posed a risk that had not been disclosed, and choosing to conceal that knowledge. If fraud can be demonstrated in civil court, liability attaches regardless of the Act's protections. The civil discovery process, which can compel the production of internal company documents, has in other sectors repeatedly produced internal communications showing that known risks were not disclosed to regulators or to the public.

What regulatory capture means and why it matters

Regulatory capture is the term used when a government body responsible for overseeing an industry begins to act in the interests of that industry rather than the public. In the context of vaccine regulation, the concern is specific and structural. In the United States, the Food and Drug Administration's drug and biologics review programmes are substantially funded by fees paid by the companies whose products are submitted for approval. The Centres for Disease Control and Prevention receives private donations through its associated foundation, including from vaccine manufacturers. Similar arrangements exist in regulatory bodies in other countries.

The concern this raises is not primarily about individual dishonesty. It is about how institutional incentives operate at scale. When a regulatory agency depends significantly on industry funding, the agency's culture tends to reflect that. Studies generating unfavourable findings find it harder to reach the published record. Safety signals that could threaten product timelines receive less sustained attention. The evidence base that policymakers rely on is shaped by the same financial relationships that shape the industry itself.

In the United States, members of advisory committees that recommend vaccination schedules can in some cases vote on products even where they hold financial interests in the companies concerned, if a waiver is granted. Critics argue the waiver process has been applied too broadly, and that these committees cannot be considered fully independent of commercial influence while those relationships persist.

What happens when scientists raise safety concerns

Dr Peter Aaby, a Danish vaccinologist who spent most of his professional career conducting field research in Guinea-Bissau in West Africa, produced some of the most significant and contested findings in this area. His research found that the DTP vaccine, which protects against diphtheria, tetanus, and whooping cough and is one of the most widely used vaccines in the world, was associated with significantly higher all-cause mortality in girls compared to unvaccinated children. The vaccine provided the intended protection against its three target diseases. The overall death rate among vaccinated girls compared to unvaccinated girls pointed to a different conclusion.

Aaby's findings were published in peer-reviewed journals and formally submitted to the World Health Organisation. The institutional response, according to researchers who examined the process, was a review that minimised the findings and led to the removal of his research funding rather than a large-scale independent investigation of the data.

Dr Judy Mikovits, a molecular biologist and virologist who worked in the United States, described a more direct form of institutional retaliation. After refusing to suppress her findings about the contamination of blood and vaccine supplies with mouse cancer-causing retroviruses (a class of viruses that insert themselves into the genetic material of host cells), she was arrested, held without charge, and placed under a legal order preventing her from speaking publicly. A whistleblower case she filed under seal with the US federal government was dropped the day after her first public appearance at a vaccine safety conference. She identified a coordinated pattern of retraction campaigns and targeted grant withdrawals against researchers whose findings threatened established institutional interests.

The significance of these cases lies in what they reveal about institutional incentives. When raising a safety concern produces reliably worse professional outcomes than staying silent, the institutions responsible for safety surveillance will systematically undercount harm. The official safety record visible to policymakers and the public will be skewed by those incentives, regardless of the individual intentions of the people working within those institutions.

Antibody-dependent enhancement: the mechanism and the evidence

Antibody-dependent enhancement (ADE) is a specific biological mechanism in which prior vaccination or infection makes a subsequent exposure to the pathogen more dangerous rather than less. Understanding why requires a brief description of how the immune system responds to vaccines.

When the immune system encounters a virus or a vaccine antigen (a small piece of the virus that the vaccine introduces), it produces antibodies of two main types. Neutralising antibodies bind to the virus and block it from entering cells, effectively disabling it. Binding antibodies attach to the virus but do not block entry. In certain conditions, binding antibodies can act as a bridge that carries the virus more efficiently into immune cells, leading to a more severe infection than would have occurred in an unvaccinated person. ADE occurs when a vaccine preferentially stimulates binding antibodies rather than neutralising antibodies, or when the neutralising antibodies produced do not work against a later variant of the virus.

This mechanism has been observed in practice. In the 1960s, a vaccine against respiratory syncytial virus (RSV, a common cause of respiratory illness, especially in children) was tested in human trials in the United States. All participants developed an antibody response that appeared to show the vaccine was working. When those participants later encountered the natural virus, instead of being protected they became severely ill. Two of the 35 child participants died. The trial was ended and the research approach was abandoned.

Following the SARS outbreaks in 2002 and 2003, researchers in multiple countries developed coronavirus vaccine candidates and selected the most promising for animal trials. All produced strong antibody responses. When the animals were subsequently exposed to the natural SARS virus, their immune responses made the disease significantly worse. The programme was terminated in 2012. Peter Hotez, a prominent vaccine scientist at Baylor College of Medicine in Texas, testified before the United States Congress on the ADE risk for coronavirus vaccines. Anthony Fauci, then director of the National Institute of Allergy and Infectious Diseases, acknowledged publicly that vaccines making recipients sicker was a documented concern. Both statements were made before the COVID-19 mass vaccination programme began.

The right to make your own medical decisions

Informed consent is a foundational principle of medical ethics and law. It holds that a patient must receive clear and complete information about a proposed medical treatment, including its known risks and any significant uncertainties, before agreeing to receive it. Crucially, the person must also be genuinely free to refuse. Informed consent is protected in medical law in most countries, in professional standards for healthcare practitioners globally, and in international frameworks including the Nuremberg Code (established after the Second World War in response to forced medical experimentation) and the Declaration of Helsinki (a set of ethical principles for medical research adopted by the World Medical Association).

When vaccination is made a condition of employment, school attendance, or access to public spaces, the consent required by law is no longer genuinely voluntary. Legal challenges to vaccine mandates have been brought in multiple countries on exactly this basis, with varying outcomes depending on the jurisdiction. What this litigation has collectively established is that the informed consent argument is viable in court, and that the standard of disclosure applied in vaccination programmes has not always met the threshold courts expect for other medical procedures.

This principle stands independently of any position on vaccine safety or efficacy. A person who supports vaccination and intends to take every recommended vaccine can still hold that the decision should be free and informed, without penalties for refusal. The argument for the right to choose is not an argument against vaccines. It is an argument about the conditions under which medical decisions should be made.

Where these ideas come from

The ideas in this section of the knowledge base originate from the work of Ty Bollinger and Charlene Bollinger, specifically The Truth About Vaccines Roundtable with the Experts, produced and distributed by TTAV Global on 13 October 2020. The Bollingers are independent health journalists and documentary filmmakers who have spent more than a decade interviewing researchers, clinicians, legal advocates, and public health critics on vaccine policy and related topics. Their roundtable format brings together multiple named experts in a single session, covering scientific, legal, and institutional dimensions of the vaccine debate. If you want to engage with the original work in full, it is available directly through TTAV Global.

The knowledge base itself is an independent work. Every concept has been studied, rewritten from scratch, and restructured for use in a multi-source advisory system. Nothing from the original has been reproduced. The knowledge has been transformed, not copied. The source is named clearly because the ideas deserve proper credit, and because the original work stands on its own merits.